Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011;16(11):1482-3.
doi: 10.1634/theoncologist.2011-0325. Epub 2011 Oct 20.

Impact of multigene assays in early stage breast cancer

Shelly S Lo  1 , Kathy S Albain
Affiliations
Comment

Impact of multigene assays in early stage breast cancer

Shelly S Lo et al. Oncologist. 2011.

Abstract

The study of Joh et al., published in this issue of The Oncologist is reviewed.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Shelly Lo: None; Kathy Albain: Genomic Health (C/A).

Comment on

References

    1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800. - PubMed
    1. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(suppl 3):S141–S145. - PubMed
    1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24:3726–3734. - PubMed
    1. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65. - PMC - PubMed
    1. Joh JE, Esposito NN, Kiluk JV, et al. The effect of Oncotype DX® recurrence score on treatment recommendations for patients with estrogen receptor positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. The Oncologist. 2011;16:1520–1526. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources